1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
n/a
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
11-20
Issue
1
Volume
11
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
A COMPARISON OF AMPICILLIN-SULBACTAM WITH CEFOXITIN IN THE TREATMENT OF LOWER RESPIRATORY-TRACT INFECTIONS OF BACTERIAL ETIOLOGY
Publisher
An entity responsible for making the resource available
Advances in Therapy
Date
A point or period of time associated with an event in the lifecycle of the resource
1994
1994-01
Subject
The topic of the resource
ampicillin sulbactam; cefoxitin; lower respiratory tract infection; Pharmacology & Pharmacy; Research & Experimental Medicine
Creator
An entity primarily responsible for making the resource
Tan J; File T M
Description
An account of the resource
Ampicillin/sulbactam (1.0-2.0 g ampicillin and 0.5-1.0 g sulbactam) and cefoxitin (1.0-2.0 g), both administered intravenously once every 6 hours, were compared in patients with lower respiratory tract infections. Thirty-two of the 51 ampicillin/sulbactam-treated patients and 24 of the 49 patients who received cefoxitin were evaluable. No significant differences were noted in the clinical and bacteriologic responses to the two antimicrobials (P = .349 and P = .473, respectively). Twenty-two (68.8%) of the ampicillin/sulbactam-treated patients were cured and 9 (28.1%) were improved; there was 1 failure. Thirteen (54.2%) patients who received cefoxitin were cured and 10 (41.7%) were improved; clinical outcome in 1 patient was not able to be determined. All isolates were eradicated in 28 (87.5%) of the patients who received ampicillin/sulbactam. The original pathogen persisted in 2 (6.3%) others. The bacteriologic response was not determined in 2 (6.3%) patients. All initial isolates were eradicated in 20 (83.3%) cefoxitin-treated patients and partially eradicated in 1 (4.2%) additional patient. In 2 (8.3%) patients, the original pathogen persisted. The bacteriologic response was not determined in 1 (4.2%) patient. Adverse reactions occurred with approximately equal frequency in both groups.
Identifier
An unambiguous reference to the resource within a given context
n/a
Format
The file format, physical medium, or dimensions of the resource
Journal Article
1994
Advances in Therapy
ampicillin sulbactam
cefoxitin
File T M
Journal Article
lower respiratory tract infection
Pharmacology & Pharmacy
Research & Experimental Medicine
Tan J